Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab

Simon J Gunter; Zachary E Holcomb; Barbara D Lam; Martina L Porter; Alexa B Kimball

doi:10.1001/jamadermatol.2024.1075

Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab

JAMA Dermatol. 2024 May 8:e241075. doi: 10.1001/jamadermatol.2024.1075. Online ahead of print.

Authors

Simon J Gunter¹, Zachary E Holcomb², Barbara D Lam³, Martina L Porter^{4

5}, Alexa B Kimball^{4

5}

Affiliations

¹ Harvard Medical School, Boston, Massachusetts.
² Section of Dermatology, Department of Medicine, Carilion Clinic, Roanoke, Virginia.
³ Division of Hematology and Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
⁴ Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
⁵ Department of Dermatology, Harvard Medical School, Boston, Massachusetts.

PMID: 38717768
PMCID: PMC11079783 (available on 2025-05-08)
DOI: 10.1001/jamadermatol.2024.1075

No abstract available

Plain language summary

This post hoc analysis of PIONEER I and II randomized clinical trials assessed whether receiving adalimumab was associated with decreased hematologic abnormalities and increased clinical improvement in patients with hidradenitis suppurativa.